Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2618960 in Healthy Volunteers
NCT02293161Phase 1Completed
- Sponsor
- GSK
- Start
- Nov 2014
- Primary completion
- Sep 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK2618960 in autoimmune diseases (4 cohorts), sponsored by GSK. Primary endpoints: Number of Participants with Adverse events (AE), Absolute values of vital signs and 4 more. Started Nov 2014; status: completed.
02
Drugs
GSK2618960
03
Conditions
autoimmune diseases
Beyond the preview
Go deeper on NCT02293161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02293161.